Literature DB >> 17897042

Implications of the obesity epidemic for statin therapy: shifting cholesterol metabolism to a high synthesis and low dietary absorption state.

Michel R Hoenig1, Karam M Kostner, Stephen J Read, Philip J Walker, John J Atherton.   

Abstract

Obesity and the metabolic syndrome are becoming one of the biggest health challenges of the 21(st) century. Cholesterol metabolism is significantly altered in both obesity and metabolic syndrome in that cholesterol synthesis is increased and absorption reduced and this has important implications for the treatment of lipid disorders in both obesity and the metabolic syndrome. In the present review we discuss these changes in detail especially in the context of a more standardized approach for cholesterol reduction like the TARGET LDL trial. Customized care is topical in lipidology as we strive to achieve LDL cholesterol and non-HDL cholesterol targets in every patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897042     DOI: 10.2174/187153007781662567

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  5 in total

1.  Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.

Authors:  B R Ito; B-H Zhang; E E Cable; X Song; J M Fujitaki; D A MacKenna; C E Wilker; B Chi; P D van Poelje; D L Linemeyer; M D Erion
Journal:  Br J Pharmacol       Date:  2009-01-22       Impact factor: 8.739

2.  Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: a magnetic resonance imaging study.

Authors:  Michel R Hoenig; Gary Cowin; Raymond Buckley; Christine McHenery; Allan Coulthard
Journal:  Lipids Health Dis       Date:  2011-01-19       Impact factor: 3.876

Review 3.  Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target.

Authors:  Michel R Hoenig
Journal:  Vasc Health Risk Manag       Date:  2008

4.  Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.

Authors:  Jeffrey B Rosen; Jose G Jimenez; Valdis Pirags; Hella Vides; Rachid Massaad; Mary E Hanson; Philippe Brudi; Joseph Triscari
Journal:  Lipids Health Dis       Date:  2013-07-16       Impact factor: 3.876

5.  Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma.

Authors:  Owein Guillemot-Legris; Valentin Mutemberezi; Patrice D Cani; Giulio G Muccioli
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.